History
A list of downloadable documents created during development.
Background information
Multiple myeloma (first line) - bortezomib and thalidomide: equality impact assessment
Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination (post appeal)
Multiple myeloma (first line) - bortezomib and thalidomide: appeal
Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination
-
Multiple myeloma (first line) - bortezomib and thalidomide: consultee and commentator comments on the ACD
-
Multiple myeloma (first line) - bortezomib and thalidomide: manufacturer comments
-
Multiple myeloma (first line) - bortezomib and thalidomide: Janssen-Cilag
-
Multiple myeloma (first line) - bortezomib and thalidomide: patient and professional groups
-
Multiple myeloma (first line) - bortezomib and thalidomide: commentator comments
Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation
-
Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation
-
Multiple myeloma (first line)- bortezomib and thalidomide: evaluation report
-
Assessment report
-
Consultee and commentator comments on the assessment report
-
Non-manufacturer submissions
-
Myeloma UK (Supported by Leukaemia CARE and Macmillan Cancer Support)
-
Manufacturer submissions